praluent
praluent Uses, Dosage, Side Effects, Food Interaction and all others data.
praluent is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.
praluent reduces levels of PCSK9 in a concentration-dependent manner.
| Trade Name | praluent |
| Availability | Prescription only |
| Generic | Alirocumab |
| Alirocumab Other Names | Alirocumab |
| Related Drugs | Vascepa, Praluent, Nexletol, Nexlizet, Zetia, Repatha, atorvastatin, Xarelto, simvastatin, rosuvastatin |
| Weight | 150mg, 75mg, |
| Type | Injection, Solution |
| Formula | C6472H9996N1736O2032S42 |
| Weight | 146000.0 Da |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | Sanofi Aventis Groupe, Sanofi |
| Available Country | Saudi Arabia, Australia, Canada, United Kingdom, United States, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
praluent is a PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C).
praluent is an antibody eliciting proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor activity that is indicated for:
(i) use in reducing the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease , and/or
(ii) use as an adjunct to diet or use alone or in combination with other lipid-lowering therapies (statins, ezetimibe, for example) for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol (LDL-C) levels in the body .
praluent is also used to associated treatment for these conditions: Heterozygous Familial Hypercholesterolemia, Myocardial Infarction, Stroke, Unstable Angina Pectoris, Primary Hyperlipidemia
How praluent works
praluent is a fully human IgG1 monoclonal antibody that binds and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme found to have "gain of function" mutations in autosomal dominant hypercholesterolemia. PCSK9 is secreted by the liver and typically binds to the LDL receptors in serum and marks them for lysosomal degradation. In result, the LDL receptors are not able to recycle to the plasma membrane, reducing their binding to LDL-C and therefore reducing the clearance of LDL-C from plasma. Therefore by inhibiting PCSK9's actions, alirocumab allows for more LDL-C reuptake by the liver and facilitates a higher rate of clearance. Lower LDL cholesterol concentrations are associated with a reduced risk of coronary heart disease.
Food Interaction
No interactions found.Volume of Distribution
praluent is mainly distributed through the circulatory system, with minimal extravascular distribution.
Elimination Route
Following subcutaneous (SC) administration, alirocumab is absorbed into the bloodstream and maximum concentrations are reached at a median time of 3-7 days. The absolute availability after SC administration was 85%.
Half Life
In monotherapy, the median half-life of alirocumab at steady state was 17–20 days in patients receiving alirocumab at SC doses of 75 or 150 mg every 2 weeks. As statin therapy increases the production of PCSK9, statin co-administration is thought to shorten alirocumab half-life; therefore the median apparent half-life of alirocumab was reduced to 12 days at equivalent alirocumab doses. However, this difference is not considered clinically significant and does not change dosing recommendations.
Innovators Monograph
You find simplified version here praluent
